June 14, 2018

Merrill Insight™ Video Healthcare M&A Spotlight: Webinar Playback and Transcript

What are the hottest and most underinvested areas in healthcare today? Why are more biotechs considering listing on the Hong Kong Stock Exchange? What are the drivers behind roll-ups in the UK and US, and which industries are ripe for more? How should wealthy investors decide where to invest their money?

A 500+ live video audience watched panelists debate these questions and more during our June Merrill Insight™ Video on healthcare M&A. Moderated by Merrill Insight™ Director Abby Roberts, panelists included:

  • Joseph Katz, Director of Healthcare M&A at PwC
  • Laurie Burlingame, Life Sciences Partner at Goodwin Procter
  • Taylor Phelps, Managing Director of Healthcare at Raymond James
  • Kimberly Ha, Founder & CEO, KKH Advisors

You can access the on-demand playback by completing the form.

Don't like video or want to follow-up on something that piqued your interests? Read the full transcript here.

You may also like:

As the tide turns, what’s next? H2 2022 Market Outlook

Join Datasite as we unpack insights and trends from our global M&A report in partnership with PitchBook. In this on-demand webinar, Datasite and PitchBook will host a panel of M&A leaders to unearth their H2 2022 market outlook, challenges, opportunities, and best practices amid a pivotal year.

Investment banker runs along a beach
M&A Deal Momentum: Influence of ESG on APAC Dealmaking

In the webinar, we will take a deep dive into to the fast-evolving and profoundly important area of ESG in APAC, analyzing the extent to which it is driving and transforming dealmaking in the region, which sectors are being impacted most, and what role technology is playing in diligence to execution.

Democratization of private equity

The emergence of retail investor/public investor money coming into private equity and several investment platforms are really starting to ‘democratize’ access to private equity. Is this connected with the growing number of IPOs that we are seeing for PE firms?